Current Edition


Revance’s Botox rival turned away by FDA after inspectors flagged manufacturing ‘deficiencies’

Despite a pandemic delay and an FDA warning about quality control and record-keeping problems at a production site, Revance insisted it was optimistic the agency …

Continue Reading →

As Revance nears a potential launch for its Botox rival, AbbVie sues for patent infringement

Revance Therapeutics has traveled a long road to a potential FDA approval for its Botox competitor, including COVID delays that pushed back plant inspections. Now, …

Continue Reading →